- Home
- PAXS vs IVA Comparison
PAXS vs IVA Comparison
Compare PAXS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- IVA
- Stock Information
- Founded
- PAXS 2021
- IVA 2011
- Country
- PAXS United States
- IVA France
- Employees
- PAXS N/A
- IVA N/A
- Industry
- PAXS Investment Managers
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- IVA Health Care
- Exchange
- PAXS Nasdaq
- IVA Nasdaq
- Market Cap
- PAXS 723.1M
- IVA 769.0M
- IPO Year
- PAXS N/A
- IVA 2020
- Fundamental
- Price
- PAXS $16.29
- IVA $5.56
- Analyst Decision
- PAXS
- IVA Strong Buy
- Analyst Count
- PAXS 0
- IVA 6
- Target Price
- PAXS N/A
- IVA $15.33
- AVG Volume (30 Days)
- PAXS 195.0K
- IVA 71.5K
- Earning Date
- PAXS 01-01-0001
- IVA 09-26-2025
- Dividend Yield
- PAXS 11.72%
- IVA N/A
- EPS Growth
- PAXS N/A
- IVA N/A
- EPS
- PAXS N/A
- IVA N/A
- Revenue
- PAXS N/A
- IVA $14,591,573.00
- Revenue This Year
- PAXS N/A
- IVA $80.35
- Revenue Next Year
- PAXS N/A
- IVA N/A
- P/E Ratio
- PAXS N/A
- IVA N/A
- Revenue Growth
- PAXS N/A
- IVA N/A
- 52 Week Low
- PAXS $12.57
- IVA $1.53
- 52 Week High
- PAXS $15.93
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- PAXS 73.16
- IVA 59.10
- Support Level
- PAXS $15.46
- IVA $5.21
- Resistance Level
- PAXS $16.46
- IVA $5.78
- Average True Range (ATR)
- PAXS 0.10
- IVA 0.37
- MACD
- PAXS 0.02
- IVA -0.03
- Stochastic Oscillator
- PAXS 76.39
- IVA 49.75
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.